In this study, we first checked whether the immunoprofiles of biopsied HCCs, which contain only small portions of tumor, can represent those of whole tumor, by comparing the immunoprofiles of stemness (K19, EpCAM, and CD133), hypoxia (carbonic anhydrase IX [CAIX] and vascular endothelial growth factor [VEGF]), and tumor stromal markers (α-smooth muscle actin [α-SMA] and fibroblast activation protein [FAP]) between matched biopsied and resected HCCs in non-TACE group. The gene discussed is FAP; the disease is neoplasm.